Investigating the link between physical activity and heart disease in older adults
Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy
This study is trying to see if staying active throughout life can help older adults, including those with heart disease, understand their risk of developing a specific type of heart condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 189 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Medical University of Graz Academic / other |
| Locations | 1 site (Graz) |
| Trial ID | NCT06261216 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It focuses on individuals aged over 60, including those diagnosed with wtATTR-CM, heart failure, or healthy controls. The study will involve interviews to gather data on participants' physical activity levels and specific sports disciplines to identify potential correlations with the disease. The findings could enhance understanding of risk factors associated with this increasingly recognized cardiac condition.
Who should consider this trial
Good fit: Ideal candidates include individuals over 60 years old with a confirmed diagnosis of wtATTR-CM, heart failure, or healthy individuals without heart disease.
Not a fit: Patients with severe chronic illnesses that limit physical activity or those with known disease-causing variants in the TTR gene may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into lifestyle factors that may influence the development of wild-type transthyretin amyloid cardiomyopathy, potentially guiding preventive strategies.
How similar studies have performed: While there is growing interest in the relationship between physical activity and cardiac conditions, this specific association with wild-type transthyretin amyloid cardiomyopathy is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmed diagnosis of wtATTR-CM including sequencing of the TTR gene; or HF; or healthy proband without a diagnosis of heart disease 2. Initial diagnosis of respective cardiac disease (wtATTR-CM, HF) after the 6th decade of life; or no cardiac disease (healthy control) 3. Willingness and ability to provide signed informed consent form (ICF) 4. Age \> 60 years Exclusion Criteria: 1. History of severe chronic illness limiting the ability to perform physical activity during the 3rd to 6th decade 2. A diagnosis of dementia or cognitive impairment 3. Any other reason resulting in the inability to perform the questionnaire and/or interview 4. Known disease-causing variant (pathogenic or likely-pathogenic) in the TTR gene
Where this trial is running
Graz
- Medical University of Graz — Graz, Austria (Recruiting)
Study contacts
- Principal investigator: Nicolas Verheyen, Res Prof, MD PhD — Medical University of Graz
- Study coordinator: Nicolas Verheyen, Res Prof, MD PhD
- Email: nicolas.verheyen@medunigraz.at
- Phone: 0043 316 385 30173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.